Friday 6 November 2026 Export ARQT’s income statement to Excel — free account

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.

Revenue: +45.1%
EPS: +12.0%
Free cash flow: +1,171.9%
Total debt: +0.83%

Quarter to September 2026, against a year earlier

25.55 1.45 −5.37%

Follow ARQT

Alert me

Market cap: $3.4B
P/E: 112×
Fwd P/E: 81.2×
Dividend yield: —
F-score: 4/9
Altman Z: 6.98
Beneish M: −1.52
Dividend safety: n/a

Overview

Arcutis Biotherapeutics, Inc. (ARQT) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, Arcutis Biotherapeutics, Inc. (ARQT) trades at a P/S ratio of 6.6×. Over the past ten years it has ranged from 0.0× (June 2023) to 57.9× (July 2023); the current reading is higher than 56% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ARQT/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Arcutis Biotherapeutics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ARQT/metrics/ps-ratio">Arcutis Biotherapeutics, Inc. (ARQT) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	9.8×	14.60%
FY2024	8.6×	114.96%
FY2023	4.0×	—
FY2022	0.0×	—

Period	P/S ratio	Change
Sep 2026	6.8×	(7.71%)
Jun 2026	7.4×	0.58%
Mar 2026	7.3×	(25.36%)
Dec 2025	9.8×	29.84%
13 more quarters	Free account

Against its own ten years

Low 0.0× High 57.9×

Ten-year median 0.0×

Current reading's percentile 18

Company	P/S ratio
DFTX Definium Therapeutics, Inc. compare	n/m
EWTX Edgewise Therapeutics, Inc. compare	n/m
LEGN Legend Biotech Corporation Sponsored ADR compare	3.3×
ARQT Arcutis Biotherapeutics, Inc.	7.0×
IOVA Iovance Biotherapeutics, Inc. compare	9.3×
TNGX Tango Therapeutics, Inc. compare	51.0×
ABCL AbCellera Biologics Inc. compare	51.9×
RLAY Relay Therapeutics, Inc. compare	313×
DNTH Dianthus Therapeutics, Inc. compare	1,763×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Arcutis Biotherapeutics, Inc. (ARQT) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ARQT

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ARQT

Stockrow Weekly